Avelumab has been filed for use in patients ... Merck Inc and Pfizer had seemed like outsiders in the immunotherapy race just two years ago, when PD-1 inhibitors Merck’s Keytruda and BMS ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

Avelumab is described as a human anti-programmed ... I and preliminary Phase II data from the trial at the Society for Immunotherapy of Cancer (SITC) 39th annual meeting. This data showed ...

PT-112—a platinum-containing immunotherapy agent Phosplatin is ... Pfizer and Merck KGaA on a combination study of PT-112 and avelumab in solid tumors, and a sub-licensing agreement for Greater ...

An analysis of blood and tumor samples from patients in a clinical trial comparing two therapies for advanced renal cell carcinoma shows that different immunomodulatory mechanisms are at work ...

Germany will supply avelumab for the study. The Phase II open-label study is expected to accrue up to 50 patients with metastatic CRC who are both chemotherapy- and immunotherapy-refractory and ...

immunotherapy has emerged as a promising alternative. Recent studies have explored the efficacy of anti-PD-1 and anti-PD-L1 therapies, such as pembrolizumab and avelumab, in treating ...